Tel Aviv (August 27th, 2018) – BioLight is pleased to announce that today, its subsidiary IOPtima Ltd., (“IOptima”) , announced receipt of a renewal of its regulatory approval for marketing and selling the IOPtiMateTM System in China, from the Chinese Food and Drug Administration (“CFDA”), for a period of 5 years until 2023.
IOptima has a distribution agreement in China with the Chinese pharmaceutical company Chengdu Kanghong Pharmaceutical Group Co with whom a final and binding agreement for the investment in and the acquisition in stages of IOPtima was signed on November 2017.
Link to Newsroom